Pharmachronicles

Top Menu

  • Home
  • Our Blog
  • Contact Us

Main Menu

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
Sign in / Join

Login

Welcome! Login in to your account
Lost your password?

Lost Password

Back to login
  • Home
  • Our Blog
  • Contact Us

logo

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
  • Overcoming Vaccine Hesitancy: How Pharmacists Build Patient Confidence

  • Resurgence of COVID-19 in Hong Kong and Singapore: A New Wave Driven by Waning Immunity and Emerging Variants

  • How Pharmacists Support Chronic Disease Management in the Community

  • OTC Medications: Safe Use, Common Mistakes, and Pharmacist Guidance

  • Pharmacovigilance Explained: Why Reporting Adverse Drug Reactions Saves Lives

BLOGS
Home›BLOGS›FDA approves pill with sensor

FDA approves pill with sensor

By admin
November 15, 2017
1285
0
Share:

The U.S. Food and Drug Administration approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults.

The system works by sending a message from the pill’s sensor to a wearable patch. The patch transmits the information to a mobile application so that patients can track the ingestion of the medication on their smart phone. Patients can also permit their caregivers and physician to access the information through a web-based portal.

“Being able to track ingestion of medications prescribed for mental illness may be useful for some patients,” said Mitchell Mathis, M.D., director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research. “The FDA supports the development and use of new technology in prescription drugs and is committed to working with companies to understand how technology might benefit patients and prescribers.”

It is important to note that Abilify MyCite’s prescribing information (labeling) notes that the ability of the product to improve patient compliance with their treatment regimen has not been shown. Abilify MyCite should not be used to track drug ingestion in “real-time” or during an emergency because detection may be delayed or may not occur.

Schizophrenia is a chronic, severe and disabling brain disorder. About 1 percent of Americans have this illness. Typically, symptoms are first seen in adults younger than 30 years of age. Symptoms of those with schizophrenia include hearing voices, believing other people are reading their minds or controlling their thoughts, and being suspicious or withdrawn. Bipolar disorder, also known as manic-depressive illness, is another brain disorder that causes unusual shifts in mood, energy, activity levels and the ability to carry out day-to-day tasks. The symptoms of bipolar disorder include alternating periods of depression and high or irritable mood, increased activity and restlessness, racing thoughts, talking fast, impulsive behavior and a decreased need for sleep.

Abilify MyCite contains a Boxed Warning alerting health care professionals that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Abilify MyCite is not approved to treat patients with dementia-related psychosis. The Boxed Warning also warns about an increased risk of suicidal thinking and behavior in children, adolescents and young adults taking antidepressants. The safety and effectiveness of Abilify MyCite have not been established in pediatric patients. Patients should be monitored for worsening and emergence of suicidal thoughts and behaviors. Abilify MyCite must be dispensed with a patient Medication Guide that describes important information about the drug’s uses and risks.

In the clinical trials for Abilify, the most common side effects reported by adults taking Abilify were nausea, vomiting, constipation, headache, dizziness, uncontrollable limb and body movements (akathisia), anxiety, insomnia, and restlessness. Skin irritation at the site of the MyCite patch placement may occur in some patients.

Prior to initial patient use of the product, the patient’s health care professional should facilitate use of the drug, patch and app to ensure the patient is capable and willing to use the system.

Abilify was first approved by the FDA in 2002 to treat schizophrenia. The ingestible sensor used in Abilify MyCite was first permitted for marketing by the FDA in 2012.

The FDA granted the approval of Abilify MyCite to Otsuka Pharmaceutical Co., Ltd. The sensor technology and patch are made by Proteus Digital Health.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

source: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm584933.htm

TagsfdaPILLSENSOR
Previous Article

Cell replacement therapy for parkinson’s disease

Next Article

Non immune engineered cells that can kill ...

0
Shares
  • 0
  • +
  • 0
  • 0
  • 0
  • 0

admin

Related articles More from author

  • FDA AlertsMedical & HealthMedical research

    FDA approves a new clinical trial for non-healing wounds.

    October 28, 2017
    By admin
  • FDA Alerts

    FDA Approves Humanized Monoclonal Antibody For Migraine Treatment.

    September 30, 2018
    By Pharmachronicles
  • BLOGS

    Can biotin manipulate lab test

    August 28, 2018
    By admin
  • Trials

    Progression of rare connective tissue tumor controlled by targeted therapy

    December 26, 2018
    By Ramoju kishore kumar
  • FDA Alerts

    FDA approves a new drug to treat malaria which could help millions.

    July 24, 2018
    By Pharmachronicles
  • BLOGS

    FDA is carefully evaluating prescription opioid medications approved to treat cough in children

    July 16, 2015
    By admin

Leave a reply Cancel reply

You may interested

  • BLOGS

    Difference between side effect and adverse effect of drugs

  • BLOGS

    Treating Hereditary blindness by gene therapy will be a revolution in medical field

  • Educational news

    Positive vibes for Doctor of pharmacy graduates

  • LATEST REVIEWS

  • TOP REVIEWS

  • Pharmacists are not eligible for certificate program of community health

    0
  • A New Class of Antimicrobials Has Just Been Found in Human Breast Milk Fresh super ...

    0

Timeline

  • May 20, 2025

    Overcoming Vaccine Hesitancy: How Pharmacists Build Patient Confidence

  • May 17, 2025

    Resurgence of COVID-19 in Hong Kong and Singapore: A New Wave Driven by Waning Immunity and Emerging Variants

  • May 9, 2025

    How Pharmacists Support Chronic Disease Management in the Community

  • May 9, 2025

    OTC Medications: Safe Use, Common Mistakes, and Pharmacist Guidance

  • May 7, 2025

    Pharmacovigilance Explained: Why Reporting Adverse Drug Reactions Saves Lives

Latest Comments

  • Pharmachronicles
    on
    February 27, 2025
    Thank you sir

    Streamlining Salaries through Payment Credit System and Other Benefits for Pharmacy Professionals: Suggestive Measures for PCI ...

  • G Krishna moorthy
    on
    February 1, 2025
    Good 👍 efforts Congratulations Continue your valuable professional services

    Streamlining Salaries through Payment Credit System and Other Benefits for Pharmacy Professionals: Suggestive Measures for PCI ...

  • Aarati sonawane
    on
    January 31, 2025
    Use in toppical application

    Role of Artificial Intelligence in 3D Printing Personalized Medication

  • Sowmya V
    on
    December 13, 2019
    Nice keep it up

    Blood Test Might Predict Pregnancy Due Date and Preterm Birth

Find us on Facebook

Follow Us on Instagram

logo

Dui viverra Faucibus aliquet quis phasellus accumsan. Donec et facilisis sociosqu sed tortor elit eu aliquid turpis ridiculus.

Fly, shall, have greater fifth spirit midst under from stars thing is, had creepeth multiply kind. Man may they’re meat years have third bring replenish air two light deep fill.

About us

  • Dr.N.Sriram, Founder CEO, Pharmachronicles, HITS college of Pharmacy, Ghatkesar, Hyderabad, India
  • 9704361947
  • pharmachronicles@gmail.com
  • Recent

  • Popular

  • Comments

  • Overcoming Vaccine Hesitancy: How Pharmacists Build Patient Confidence

    By Pharmachronicles
    May 20, 2025
  • Resurgence of COVID-19 in Hong Kong and Singapore: A New Wave Driven by Waning Immunity ...

    By Pharmachronicles
    May 17, 2025
  • How Pharmacists Support Chronic Disease Management in the Community

    By Pharmachronicles
    May 9, 2025
  • OTC Medications: Safe Use, Common Mistakes, and Pharmacist Guidance

    By Pharmachronicles
    May 9, 2025
  • pharmacy credit system

    Streamlining Salaries through Payment Credit System and Other Benefits for Pharmacy Professionals: Suggestive Measures for ...

    By Pharmachronicles
    February 1, 2025
  • Blood Test Might Predict Pregnancy Due Date and Preterm Birth

    By Sundari srinidhi
    December 12, 2019
  • Ai in 3D printing

    Role of Artificial Intelligence in 3D Printing Personalized Medication

    By Pharmachronicles
    January 29, 2025
  • FDA is carefully evaluating prescription opioid medications approved to treat cough in children

    By admin
    July 16, 2015
  • Pharmachronicles
    on
    February 27, 2025

    Streamlining Salaries through Payment Credit System and Other Benefits for Pharmacy Professionals: Suggestive Measures for PCI ...

    Thank you sir
  • G Krishna moorthy
    on
    February 1, 2025

    Streamlining Salaries through Payment Credit System and Other Benefits for Pharmacy Professionals: Suggestive Measures for PCI ...

    Good 👍 efforts Congratulations ...
  • Aarati sonawane
    on
    January 31, 2025

    Role of Artificial Intelligence in 3D Printing Personalized Medication

    Use in toppical application
  • Sowmya V
    on
    December 13, 2019

    Blood Test Might Predict Pregnancy Due Date and Preterm Birth

    Nice keep it up

Photostream

    Follow us

    • Contact
    • STUDENTS ZONE
    • About Us
    © Copyright Pharmachronicles. All rights reserved.